natgillin/translations-raw huggingface dataset:
Telmisartan Actavis is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. 
Zdravilo Telmisartan Actavis se uporablja tudi za zmanjševanje srčnožilnih dogodkov (npr. srčnega napada ali možganske kapi) pri odraslih s tveganjem zaradi zmanjšane ali blokirane oskrbe srca ali nog s krvjo, ali pri odraslih, ki so doživeli možgansko kap ali imajo sladkorno bolezen z velikim tveganjem.
When initiating telmisartan therapy for the reduction of cardiovascular morbidity, close monitoring of blood pressure is recommended, and if appropriate adjustment of medications that lower blood pressure may be necessary. 
Ob uvedbi telmisartana za zmanjšanje srčnožilne obolevnosti je priporočljivo natančno kontrolirati krvni tlak; potrebna je lahko prilagoditev zdravil za znižanje krvnega tlaka, če je ustrezno.
In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate. 
Bolnikom s hipertenzijo telmisartan zniža sistolični in diastolični krvni tlak, ne da bi vplival na srčno frekvenco.
Furthermore, orthostatic hypotension may be aggravated by alcohol, barbiturates, narcotics or antidepressants. 
Poleg tega lahko ortostatsko hipotenzijo poslabšajo alkohol, barbiturati, narkotiki ali antidepresivi.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Neželeni učinki so razvrščeni po oznakah pogostnosti upoštevaje naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000
There is limited information available with regard to overdose in humans. 
Informacij o prevelikem odmerjanju pri človeku je malo.
Suggested measures include induction of emesis and / or gastric lavage. 
Predlagani ukrepi vključujejo sprožitev bruhanja in/ali izpiranje želodca.
If you have the impression that the effect of Telmisartan Actavis is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Telmisartan Actavis premočan ali prešibak se o tem pogovorite z zdravnikom ali s farmacevtom.
Therefore, the use of telmisartan is not recommended. 
Zato uporaba telmisartana ni priporočljiva.
The use of Telmisartan Actavis in children and adolescents up to the age of 18 years is not recommended. 
Otroci in mladostniki Uporaba zdravila Telmisartan Actavis pri otrocih in mladostnikih do 18 leta starosti ni priporočljiva.
Angiotensin II receptor antagonists should not be initiated during pregnancy. 
Antagonistov receptorjev angiotenzina II se ne sme uvesti med nosečnostjo.
In some of the investigated patients the doses used were higher than those recommended in the treatment of hypertension in the adult population, reaching a daily dose comparable to160 mg, which was tested in adults. 
Pri nekaterih bolnikih so uporabili odmerke, ki so bili večji od priporočenih odmerkov za zdravljenje hipertenzije pri odrasli populaciji, in sicer do dnevnega odmerka, primerljivega z odmerkom po 160
The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia. 
Zdravila, ki vplivajo na sistem renin-angiotenzin-aldosteron, lahko povzročijo hiperkaliemijo.
Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returns to pre-treatment values over a period of several days without evidence of rebound hypertension. 
Po nenadnem prenehanju zdravljenja s telmisartanom se krvni tlak v nekaj dneh postopoma vrne na vrednosti pred zdravljenjem, brez znakov preobratne hipertenzije.
Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. 
O tveganju z antagonisti receptorjev angiotenzina II ni kontroliranih epidemioloških podatkov, vendar lahko s to skupino zdravil obstajajo podobna tveganja.
There is an apparent trend to a dose relationship to a time to recovery of baseline systolic blood pressure (SBP). 
Obstaja opazen trend povezanosti z odmerkom, kar zadeva čas do ponovnega doseganja izhodiščnega sistoličnega krvnega tlaka (SKT).
In patients with mild to moderate and severe renal impairment, doubling of plasma concentrations was observed. 
Pri bolnikih z blago do zmerno in hudo okvaro ledvic so ugotovili podvojitev koncentracije v plazmi.
As with any antihypertensive agent, excessive reduction of blood pressure in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke. 
Kot velja za vsa antihipertenzivna zdravila, lahko čezmerno znižanje krvnega tlaka pri bolnikih z ishemično kardiopatijo ali ishemično srčnožilno boleznijo izzove miokardni infarkt ali možgansko kap.
Telmisartan selectively binds the AT1 receptor. 
Telmisartan se selektivno veže na receptorje AT1.
The safety and efficacy of telmisartan in children and adolescents aged below 18 years have not been established. 
Varnost in učinkovitost zdravila Telmisartan Actavis pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
‘Essential' means that the high blood pressure is not caused by any other condition. 
"Esencialna" pomeni, da visok krvni tlak ni posledica kakšne druge bolezni.
Al/Al blisters: Pack sizes: 14, 28, 30, 56, 84, 90, 98 or 100 tablets. 
Al/Al pretisni omoti: 14, 28, 30, 56, 84, 90, 98 ali 100 tablet.
Total plasma clearance (Cltot) is high (approximately 1,000 ml/min) compared with hepatic blood flow (about 1,500 ml/min). 
(Cltot) je v primerjavi z jetrnim pretokom krvi (približno 1.500 ml/min) velik (približno 1.000 ml/min).
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. 
Primarni aldosteronizem Bolniki s primarnim aldosteronizmom se praviloma ne odzovejo na antihipertenzivna zdravila, ki zavirajo sistem renin-angiotenzin.
There was no evidence of mutagenicity and relevant clastogenic activity in in vitro studies and no evidence of carcinogenicity in rats and mice. 
V študijah in vitro niso ugotovili mutagenosti ali pomembnega klastogenega delovanja in tudi ne kancerogenosti pri podganah in miših.
Telmisartan does not inhibit human plasma renin or block ion channels. 
Ne zavira pa humanega renina v plazmi in tudi ne blokira ionskih kanalčkov.
Talk to your doctor before taking Telmisartan Actavis: - if you are taking digoxin. 
Posvetujte se z zdravnikom, preden boste vzeli zdravilo Telmisartan Actavis: - če jemljete digoksin
The observed increased occurrence rate of sepsis associated with the use of telmisartan may be either a chance finding or related to a mechanism not currently known. 
Opaženo večje pojavljanje sepse v povezavi z uporabo telmisartana je lahko bodisi naključno bodisi povezano z mehanizmom, ki trenutno ni poznan.
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Telmisartan Actavis. 
Z zdravnikom se morate posvetovati, ali je treba med jemanjem zdravila Telmisartan Actavis prilagoditi odmerek vašega drugega zdravila.
The all-cause mortality rate was 11.6 % and 11.8 % among telmisartan and ramipril treated patients, respectively. 
Delež umrljivosti zaradi vseh vzrokov je bil v skupini s telmisartanom 11,6 % in v skupini z ramiprilom 11,8 %.
In human, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase. 
Pri človeku odmerek 80 mg telmisartana skoraj popolnoma zavre zvišanje krvnega tlaka, izzvano z angiotenzinom II.
What Telmisartan Actavis is and what it is used for 
Kaj je zdravilo Telmisartan Actavis in za kaj ga uporabljamo
When Telmisartan Actavis is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. 
Med uporabo zdravila Telmisartan Actavis pri bolnikih z okvarjenim delovanjem ledvic so priporočljive redne kontrole kalija in kreatinina v serumu.
High blood pressure, if not treated, can damage blood vessels in several organs which could lead sometimes to heart attacks, heart or kidney failure, strokes or blindness. 
Nezdravljen visok krvni tlak lahko okvari žile na več organih in to včasih povzroči srčni infarkt, srčno popuščanje ali odpoved ledvic, možgansko kap ali slepoto.
If you forget to take your medicine you should take the dose as soon as you remember on the same day. 
Če ste pozabili vzeti zdravilo Telmisartan Actavis Če ste pozabili vzeti zdravilo, vzemite odmerek, čim se spomnite isti dan.
Such conditions should be corrected before the administration of Telmisartan Actavis . 
Takšna stanja je treba odpraviti pred uporabo zdravila Telmisartan Actavis.
Combining telmisartan with ramipril did not add further benefit over ramipril or telmisartan alone. 
Kombinacija telmisartana in ramiprila ni prinesla dodatne koristi v primerjavi z ramiprilom ali telmisartanom samim.
As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in nonblacks, possibly because of higher prevalence of low-renin states in the black hypertensive population. 
Kot kaže, tudi telmisartan in drugi antagonisti angiotenzina - tako kot zaviralci angiotenzinske konvertaze - manj učinkovito znižajo krvni tlak pri črncih kot nečrncih, verjetno zaradi večje prevalence nizkoreninskih stanj pri črni hipertenzivni populaciji.
There are no adequate data from the use of Telmisartan Actavis in pregnant women. 
O uporabi zdravila Telmisartan Actavis pri nosečnicah ni zadostnih podatkov.
Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, increase in serum creatinine, and acute renal failure have also been reported. 
Simptomi: Najpomembnejša znaka prevelikega odmerjanja telmisartana sta hipotenzija in tahikardija; opisani so bili tudi bradikardija, omotica, zvišanje kreatinina v serumu in akutna odpoved ledvic.
Telmisartan does not show affinity for other receptors, including AT2 and other less characterised AT receptors. 
Telmisartan ne kaže afinitete za druge receptorje, vključno z receptorji AT2 in drugimi, manj opredeljenimi receptorji AT.
- Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy ('water tablets'), low-salt diet, diarrhoea, 
- Nizek krvni tlak (hipotenzijo); verjetnost zanj je večja, če ste dehidrirani (ste izgubili preveč vode iz telesa), ali če vam primanjkuje soli zaradi zdravljenja z diuretiki ("tabletami za odvajanje vode"), diete z malo soli, driske ali bruhanja.
The antihypertensive efficacy of telmisartan is comparable to that of agents representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril). 
Antihipertenzivna učinkovitost telmisartana je primerljiva učinkovitosti zdravil, reprezentativnih za druge skupine antihipertenzivov (dokazano v kliničnih preskušanjih, v katerih so telmisartan primerjali z amlodipinom, atenololom, enalaprilom, hidroklorotiazidom in lizinoprilom).
In patients with mild to moderate hepatic impairment the posology should not exceed 40 mg once daily (see section 4.4). 
Pri bolnikih z blago do zmerno okvaro jeter odmerek ne sme preseči 40 mg enkrat na dan (glejte poglavje 4.4).
Treatment: Telmisartan is not removed by haemodialysis. 
Zdravljenje: Hemodializa ne odstrani telmisartana.
Telmisartan showed a similar effect to ramipril in reducing the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure. 
Telmisartan je pokazal podoben učinek kot ramipril, kar zadeva zmanjšanje primarnega sestavljenega opazovanega dogodka srčnožilne smrti, miokardnega infarkta brez smrtnega izida, možganske kapi brez smrtnega izida ali hospitalizacije zaradi kongestivnega srčnega popuščanja.
Telmisartan Actavis is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile. 
Okvara jeter Zdravila Telmisartan Actavis ne smejo dobiti bolniki s holestazo, biliarnimi obstruktivnimi motnjami ali hudo okvaro jeter (glejte poglavje 4.3), ker se telmisartan v glavnem izloča z žolčem.
Visual disturbance 
motnja vida
Angiotensin II is a substance produced in your body, which causes your blood vessels to narrow, thus increasing your blood pressure. 
Angiotenzin II je snov, ki nastaja v telesu in povzroči zožitev žil, s čimer zviša krvni tlak.
Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and followed for a mean observation time of 4.5 years. 
Bolnike so randomizirali v eno od naslednjih treh terapevtskih skupin: 80 mg telmisartana (n = 8542), 10 mg ramiprila (n = 8576) ali kombinacijo 80 mg telmisartana in 10 mg ramiprila (n = 8502).
The recommended dose is 80 mg once daily. 
80 mg enkrat na dan.
These patients can be expected to have reduced hepatic clearance for telmisartan. 
Pri teh bolnikih je mogoče pričakovati manjši jetrni očistek telmisartana.
The effect of Telmisartan Actavis may be reduced when you take NSAIDs (non steroidal anti-inflammatory drugs, e.g. aspirin or ibuprofen) or corticosteroids. 
Učinek zdravila Telmisartan Actavis se lahko zmanjša, če jemljete NSAID (nesteroidna protivnetna zdravila, npr. acetilsalicilna kislina ali ibuprofen) ali kortikosteroide.
Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. 
Telmisartan je peroralno aktiven in specifičen antagonist receptorjev angiotenzina II (tipa AT1).
Volume and/or sodium depletion should be corrected prior to administration of Telmisartan Actavis . 
Hipovolemijo in/ali hiponatriemijo je treba odpraviti pred uporabi zdravila Telmisartan Actavis.
This is confirmed by trough to peak ratios consistently above 80% seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies. 
To potrjuje razmerje med najmanjšim in največjim, ki je po odmerkih 40 in 80 mg telmisartana dosledno nad 80 %, kot so pokazale s placebom kontrolirane klinične študije.
- Diabetes. 
- Sladkorno bolezen.
Talk to your doctor if you are suffering or have ever suffered from any of the following conditions or illnesses: - Kidney disease or kidney transplant. 
Zdravniku morate povedati, če imate ali ste kdaj imeli katero od naslednjih bolezni ali motenj:
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. 
Telmisartan z zelo veliko afiniteto izpodrine angiotenzin II z njegovih vezavnih mest na podvrsti receptorjev AT1, ki so odgovorni za znane učinke angiotenzina II.
In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC0-24 and Cmax of ramipril and ramiprilat. 
V eni študiji je sočasna uporaba telmisartana in ramiprila povzročila do 2,-kraten porast AUC0-24 in Cmax ramiprila in ramiprilata.
Abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting Dry mouth, stomach discomfort, dysgeusia 
bolečine v trebuhu, driska, dispepsija, flatulenca, bruhanje suha usta, nelagodje v želodcu, disgevzija
Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin. 
Prav tako ne zavira angiotenzinske konvertaze (kininaze II), encima, ki tudi razgrajuje bradikinin.
- Renal artery stenosis (narrowing of the blood vessels to one or both kidneys). 
- Stenozo ledvične arterije (zožitev žil v eno ali obe ledvici).
Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium. 
Diuretiki, ki varčujejo s kalijem, npr. spironolakton, eplerenon, triamteren ali amilorid, dodatki kalija ali nadomestki soli, ki vsebujejo kalij, lahko močno zvišajo kalij v serumu.
- Elevated potassium levels in your blood. 
- Zvišano koncentracijo kalja v krvi.
** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan. 
** Poročali so o primerih progresivnega brazgotinjenja pljučnega tkiva med jemanjem telmisartana,
- Digoxin. 
- Digoksin
Telmisartan is highly bound to plasma protein in renal-insufficient patients and cannot be removed by dialysis. 
Telmisartan je pri bolnikih z zmanjšanim delovanjem ledvic v veliki meri vezan na beljakovine v plazmi in ga z dializo ni mogoče odstraniti.
There is no evidence of clinically relevant accumulation of telmisartan taken at the recommended dose. 
Ni dokazov, da bi med uporabo priporočenih odmerkov telmisartana prišlo do klinično pomembnega kopičenja.
Talk to your doctor before taking Telmisartan Actavis: 
Posvetujte se z zdravnikom, preden boste vzeli zdravilo Telmisartan Actavis:
What Telmisartan Actavis is and what it is used for What you need to know before you take Telmisartan Actavis How to take Telmisartan Actavis Possible side effects 
Kaj je zdravilo Telmisartan Actavis in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Telmisartan Actavis Kako jemati zdravilo Telmisartan Actavis
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5% CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13). 
Razmerje ogroženost za telmisartan v primerjavi z ramiprilom je bilo 1,01 (97,5 % IZ 0,931,10, p (neinferiornost) = 0,0019 ob meji 1,13).
These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor antagonists, do not appear to have clinical significance. 
Kot kaže, te spremembe, ki so učinek skupine zaviralcev angiotenzinske konvertaze in drugih antagonistov receptorjev angiotenzina II, niso klinično pomembne.
- if you have severe liver problems such as cholestasis or biliary obstruction (problems with the drainage of the bile from the liver and gall bladder) or any other severe liver disease. 
- če imate hude težave z jetri, npr. holestazo ali biliarno obstrukcijo (težave z odtekanjem žolča iz jeter in žolčnika) ali kakšno drugo hudo bolezen jeter.
Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter. 
Bolniki morajo biti ustrezno hidrirani; po začetku sočasnega zdravljenja in občasno med zdravljenjem je treba kontrolirati delovanje ledvic.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Telmisartan Actavis. 
Če morate dobiti anestezijo za operacijo, morate zdravniku povedati, da jemljete zdravilo Telmisartan
Telmisartan Actavis is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Uporaba zdravila Telmisartan Actavis ni priporočljiva v zgodnjem obdobju nosečnosti in ga ne smete jemati, če ste noseči več kot 3 mesece, ker lahko v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
How to store Telmisartan Actavis Contents of the pack and other information 
Shranjevanje zdravila Telmisartan Actavis Vsebina pakiranja in dodatne informacije
potassium hydroxide pellets. 
kroglice kalijevega hidroksida.
Telmisartan Actavis may be less effective in lowering the blood pressure in black patients. 
Zdravilo Telmisartan Actavis lahko pri črni rasi manj učinkovito znižuje krvni tlak.
Telmisartan Actavis may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). 
Zdravilo Telmisartan Actavis lahko poveča znižanje krvnega tlaka, ki ga povzročijo druga zdravila za zdravljenje visokega krvnega tlaka, ali zdravil z možnim antihipertenzivnim učinkom (npr. baklofen,
The safety profile of telmisartan in patients treated for the reduction of cardiovascular morbidity was consistent with that obtained in hypertensive patients. 
Varnostne značilnosti telmisartana pri bolnikih, zdravljenih za zmanjšanje srčnožilne obolevnosti, so se skladale z ugotovljenimi pri hipertenzivnih bolnikih.
Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see sections 4.3 and 4.4). 
Dojenčke, katerih matere so jemale zaviralce antagoniste receptorjev angiotenzina II, je treba natančno kontrolirati glede hipotenzije (glejte tudi poglavji 4.3 in 4.4).
There are usually no symptoms of high blood pressure before damage occurs. 
Preden se pojavi okvara, visok krvni tlak po navadi ne povzroča nobenih simptomov.
Close-monitoring of serum potassium in at risk patients is recommended (see section 4.5). 
Bolnikom s tveganjem je priporočljivo natančno kontrolirati kalij v serumu (glejte poglavje 4.5).
If you do not take your tablet on one day, take your normal dose on the next day. 
Če en dan ne vzamete tablete, vzemite običajni odmerek naslednji dan. Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjega.
The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4). 
Antagonistov receptorjev angiotenzina II (AIIR) ni priporočljivo uporabljati v prvem trimesečju nosečnosti (glejte poglavje 4.4).
Telmisartan Actavis blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. 
Telmisartan Actavis blokira učinek angiotenzina II; žile se sprostijo in krvni tlak se zniža.
Slow heart beat (bradycardia), dizziness, higher levels of creatinine in the blood and sudden kidney failure have also been reported. 
Opisani so bili tudi počasno bitje srca (bradikardija), omotica, visoka koncentracija kreatinina v krvi in nenadna odpoved ledvic.
Other medicines and Telmisartan Actavis 
Druga zdravila in zdravilo Telmisartan Actavis
If you feel dizzy or tired, do not drive or use machines. 
Ne upravljajte vozil in strojev, če ste omotični ali utrujeni.
If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended. 
Če je takšna kombinacija potrebna, je priporočljivo natančno kontrolirati koncentracijo litija v serumu.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Actavis logo 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Actavis logo
NAME OF THE MARKETING AUTHORISATION HOLDER Actavis logo 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Actavis logo
In preclinical safety studies, doses producing exposure comparable to that in the clinical therapeutic range caused reduced red cell parameters (erythrocytes, haemoglobin, haematocrit), changes in renal haemodynamics (increased blood urea nitrogen and creatinine), as well as increased serum potassium in normotensive animals. 
V predkliničnih študijah varnosti so odmerki, ki so povzročili primerljivo izpostavljenost, kot je dosežena v kliničnem terapevtskem območju, pri normotenzivnih živalih povzročili zmanjšanje eritrocitnih parametrov (eritrocitov, hemoglobina, hematokrita), spremembe ledvične hemodinamike (zvišanje sečninskega dušika in kreatinina v krvi) ter zvišanje kalija v serumu.
Gender differences in plasma concentrations were observed, Cmax and AUC being approximately 3-and 2-fold higher, respectively, in females compared to males. 
Pri ženskah je bila Cmax približno 3-krat večja, AUC pa približno 2-krat večja kot pri moških.
Cough and angioedema were less frequently reported in patients treated with telmisartan than in patients treated with ramipril, whereas hypotension was more frequently reported with telmisartan. 
Kašelj in angioedem sta bila s telmisartanom redkejša kot z ramiprilom, hipotenzija pa je bila pogostejša s telmisartanom.